These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26632357)

  • 61. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups.
    Song M
    Biotechnol Prog; 2017 Jul; 33(4):1035-1045. PubMed ID: 28440027
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Cambridge model: how public oversight of biotech is good for everyone--even business.
    Lipson S
    Genewatch; 2003; 16(5):7-10. PubMed ID: 15025120
    [No Abstract]   [Full Text] [Related]  

  • 64. CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods.
    Jo YI; Suresh B; Kim H; Ramakrishna S
    Biochim Biophys Acta; 2015 Dec; 1856(2):234-43. PubMed ID: 26434948
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Homology-Independent Integration of Plasmid DNA into the Zebrafish Genome.
    Auer TO; Del Bene F
    Methods Mol Biol; 2016; 1451():31-51. PubMed ID: 27464799
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Compelling Reasons for Repairing Human Germlines.
    Church G
    N Engl J Med; 2017 Nov; 377(20):1909-1911. PubMed ID: 29141159
    [No Abstract]   [Full Text] [Related]  

  • 67. Genetic correction using engineered nucleases for gene therapy applications.
    Li HL; Nakano T; Hotta A
    Dev Growth Differ; 2014 Jan; 56(1):63-77. PubMed ID: 24329887
    [TBL] [Abstract][Full Text] [Related]  

  • 68. CRISPR/Cas9 for genome editing: progress, implications and challenges.
    Zhang F; Wen Y; Guo X
    Hum Mol Genet; 2014 Sep; 23(R1):R40-6. PubMed ID: 24651067
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Human Genome Editing and Ethical Considerations.
    Krishan K; Kanchan T; Singh B
    Sci Eng Ethics; 2016 Apr; 22(2):597-9. PubMed ID: 26154417
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Genome editing: proceed with caution.
    The Lancet
    Lancet; 2018 Jul; 392(10144):253. PubMed ID: 30064637
    [No Abstract]   [Full Text] [Related]  

  • 71. Design and Validation of CRISPR/Cas9 Systems for Targeted Gene Modification in Induced Pluripotent Stem Cells.
    Lee CM; Zhu H; Davis TH; Deshmukh H; Bao G
    Methods Mol Biol; 2017; 1498():3-21. PubMed ID: 27709565
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Panacea in progress: CRISPR and the future of its biological research introduction.
    Carroll M; Zhou X
    Microbiol Res; 2017 Aug; 201():63-74. PubMed ID: 28602403
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [The CRISPR system can correct or modify the expression of genes responsible for hereditary diseases].
    Tremblay JP
    Med Sci (Paris); 2015 Nov; 31(11):1014-22. PubMed ID: 26576609
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The morality and ethics governing CRISPR-Cas9 patents in China.
    Peng Y
    Nat Biotechnol; 2016 Jun; 34(6):616-8. PubMed ID: 27281418
    [No Abstract]   [Full Text] [Related]  

  • 75. He Jiankui´s gene-editing experiment and the non-identity problem.
    Alonso M; Savulescu J
    Bioethics; 2021 Jul; 35(6):563-573. PubMed ID: 33951203
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Editing the mushroom.
    Hall SS
    Sci Am; 2016 Mar; 314(3):56-63. PubMed ID: 27066645
    [No Abstract]   [Full Text] [Related]  

  • 77. CRISPR technologies for bacterial systems: Current achievements and future directions.
    Choi KR; Lee SY
    Biotechnol Adv; 2016 Nov; 34(7):1180-1209. PubMed ID: 27566508
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mutagenesis and Genome Engineering of Epstein-Barr Virus in Cultured Human Cells by CRISPR/Cas9.
    Yuen KS; Chan CP; Kok KH; Jin DY
    Methods Mol Biol; 2017; 1498():23-31. PubMed ID: 27709566
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Focusing on Human Rights: a framework for CRISPR germline genome editing ethics and regulation.
    Doxzen K; Halpern J
    Perspect Biol Med; 2020; 63(1):44-53. PubMed ID: 32063585
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Time to start intervening in the human germline? A utilitarian perspective.
    Smith K
    Bioethics; 2020 Jan; 34(1):90-104. PubMed ID: 31730239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.